Clinical trials: Gastrointestinal Motility
GERD, Gastroesophageal Reflux
Observational Study of Anti-Reflux Surgery
The Anti-Reflux Surgical Study has been established to: Collect data about anti-reflux surgical treatment options (magnetic sphincter augmentation and Fundoplication) in everyday clinical practice Track the clinical course of…
- Conditions
- GERD, Gastroesophageal Reflux, Gastro Esophageal Reflux
- Trial name
- NCT01624506
- Where
- 21 sites in Austria, Germany and 2 more
- Volunteers
- 760 people
- Sponsor
- Torax Medical Incorporated
Gastroesophageal Reflux Disease (GERD)
Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to compare the efficacy of rabeprazole extended release (ER) 50 mg (once daily) versus ranitidine 150 mg (twice daily) in the maintenance of complete healing in subjects with healed erosive…
- Trial name
- NCT00838526
- Testing
- Rabeprazole ER, Ranitidine
- Where
- 4 sites in United States
- Volunteers
- 240 people
- Sponsor
- Eisai Inc.
Eosinophilic Esophagitis
Comparing Anesthetic Techniques in Children Having Esophagogastroduodenoscopies
The purpose of this research study is to compare the safety and effectiveness of three commonly used techniques for delivering anesthesia during a procedure known as esophagogastroduodenoscopy.
- Trial name
- NCT02038894
- Testing
- Intubated with Sevoflurane (IS), Intubated with Propofol (IP), Zofran - no intubation
- Where
- United States
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Gastroesophageal Reflux Disease, Obesity
Dietary Carbohydrate and GERD in Veterans
4-Arm Diet Intervention Investigating Effects of Dietary Carbohydrate Type and Amount on gastroesophageal pH, gastroesophageal reflux disease (GERD) symptoms and medication use.
- Trial name
- DietGERD (NCT02384551)
- Testing
- Dietary Carbohydrate
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- VA Office of Research and Development
Barretts Esophagus With Dysplasia
The Impact of Adjuvant Liquid Alginate on Endoscopic Ablation Therapy of Complicated Barrett's Esophagus
This study evaluates the addition of an alginate based solution to twice daily proton pump inhibitor therapy (PPI) in patients undergoing ablative therapy for dysplastic Barrett's esophagus.
- Trial name
- NCT03193216
- Testing
- Alginates
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
Gastroesophageal Reflux Disease, Erosive Esophagitis
Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets
The purpose of this study is to measure the in-vivo disintegration time of a single dexlansoprazole delayed-release orally disintegrating (OD) tablet.
- Conditions
- Gastroesophageal Reflux Disease, Erosive Esophagitis, Heartburn
- Trial name
- NCT02096458
- Testing
- Dexlansoprazole
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Takeda
Larynx Disease, Gastroesophageal Reflux
Do Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment?
The purpose of the study is to determine if tissue changes are predictor of clinical response to therapy. The hypothesis is that the patients who have laryngeal signs and symptoms related to acid reflux, will have ultrastructural…
- Trial name
- NCT00444145
- Testing
- Prevacid, Esophageal and Laryngeal Biopsies
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Vanderbilt University Medical Center
GERD
Self-Propelled Percutaneous Endoscopic GastroJejunostomy (PEG-J)
This research is being done to study the safety of an investigational percutaneous endoscopic gastrojejunostomy (PEGJ) tube and whether the addition of a balloon on the end of the J tube prevents it from slipping back into the…
- Trial name
- NCT01551095
- Testing
- PEGJ tube
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Johns Hopkins University
Gastroesophageal Reflux Disease, Heartburn
Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI
This study is being carried out to see whether AZD3355 is an effective treatment as an add-on to PPI therapy in patients with Gastroesophageal Reflux Disease (GERD) with a partial response to PPI and to compare this with Proton…
- Conditions
- Gastroesophageal Reflux Disease, Heartburn, Regurgitation
- Trial name
- NCT01005251
- Testing
- lesogaberan (AZD3355)
- Where
- United States
- Volunteers
- 661 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux
Study Evaluating Pantoprazole in Neonates and Preterm Infants With GERD
The purpose of this study is to determine whether or not consistent drug levels can be achieved in infants with presumed Gastroesophageal Reflux Disease.
- Trial name
- NCT00362609
- Testing
- pantoprazole
- Where
- 71 sites in United States, Australia and 9 more
- Volunteers
- 59 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Gastroesophageal Reflux Disease, Morbid Obesity
Gastroesophageal Reflux Disease (GERD) Before and After Gastric Bypass
The hypothesis of this study was that gastric bypass (GBP) ameliorates gastroesophageal reflux disease (GERD) in morbidly obese patients.
- Trial name
- NCT00951093
- Testing
- Gastric bypass
- Where
- Brazil
- Volunteers
- 53 people
- Sponsor
- Clinica Gastrobese
Gastroesophageal Reflux Disease
Feasibility of Placing Bravo PH Capsule in Proximal Esophagus
Assessing the feasibility and patient tolerance to placement of Bravo PH capsule in proximal esophagus. There will be no difference in patient-perception of a proximally-placed Bravo esophageal pH monitor compared with a distal…
- Trial name
- bravo (NCT00378898)
- Testing
- BRAVO capsule, Fluoroscopy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Vanderbilt University Medical Center
Gastroesophageal Reflux
Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)
To assess the efficacy of pantoprazole for the treatment of infants with symptomatic Gastroesophageal Reflux Disease (GERD).
- Trial name
- NCT00365300
- Testing
- pantoprazole
- Where
- 38 sites in United States
- Volunteers
- 129 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Barrett Esophagus, Esophageal Adenocarcinoma
Rapid Assessment of Esophageal Adenocarcinoma Risk Test
This study aims to evaluate the acceptability of a new non-invasive screening device to test for Barrett's esophagus. The investigators will prospectively enroll 100 patients to undergo Cytosponge testing.
- Trial name
- REACT (NCT03366012)
- Testing
- Cytosponge
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Columbia University
Gastroesophageal Reflux Disease (GERD)
Experimental Study to Determine the Effects of Human Refluxate on Macrophage Phenotype and Its Correlation With GERD
This study is proposed to evaluate the role of motoric dysfunctions and type of refluxate in GERD patients, analyzed the blood monocyte/macrophage phenotypes of gastroesophageal reflux diseases (GERD) patients.
- Trial name
- NCT02699060
- Testing
- Upper gastrointestinal endoscopy with biopsy and collection of refluxate, Esophageal high-resolution manometry and 24-h esophageal pH-impedance monitoring
- Where
- 2 sites in Russia
- Volunteers
- 68 people
- Sponsor
- Ivashkin Vladimir Trofimovich
Barrett's Esophagus
Prospective Study to Compare the Efficacy of E.G.Scan to Detect Barrett's Esophagus Compared With Standard Endoscopy
The purpose of this study was to evaluate whether a disposable nasal endoscope called "E.G. Scan II" will visualize the esophagus as well as the standard test, sedated endoscopy.
- Trial name
- NCT02066233
- Testing
- EG Scan II (transnasal endoscopy), Standard Endoscopy
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Gastroesophageal Reflux Disease
A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients
The purpose of this study is to assess the efficacy and safety of rabeprazole 10mg once and twice daily in maintenance therapy for PPI resistant gastroesophageal reflux disease patients.
- Trial name
- NCT02135107
- Testing
- Rabeprazole
- Where
- 61 sites in Japan
- Volunteers
- 517 people
- Sponsor
- Eisai Co., Ltd.
Symptomatic Gastroesophageal Reflux Disease (sGERD)
Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)
The purpose of this study is to compare the efficacy, safety and tolerability of rabeprazole extended release (ER) 50 mg with placebo in subjects with symptomatic gastroesophageal reflux disease (sGERD).
- Trial name
- NCT00911534
- Testing
- rabeprazole sodium
- Where
- 98 sites in United States
- Volunteers
- 305 people
- Sponsor
- Eisai Inc.
Gastroesophageal Reflux Disease, Dyspepsia
Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study
This study is being conducted to provide evidence that Compound Sodium Alginate Double Action Chewable Tablets are effective in managing the symptoms of heartburn, acid regurgitation and dyspepsia in patients with…
- Trial name
- NCT01869491
- Testing
- Compound Sodium Alginate Double Action Chewable Tablets
- Where
- 2 sites in China
- Volunteers
- 1,107 people
- Sponsor
- Reckitt Benckiser Healthcare (UK) Limited
GERD, Acid Reflux Disease
Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms
This research study is being done to gather information about how to do further clinical studies using AZD3355 as an add-on treatment to proton pump inhibitors (PPI).
- Conditions
- GERD, Acid Reflux Disease, Heartburn, Regurgitation
- Trial name
- C27 (NCT00703534)
- Testing
- AZD3355, Gelusil®
- Where
- 84 sites in United States
- Volunteers
- 478 people
- Sponsor
- AstraZeneca